Journal
JOURNAL OF CELL SCIENCE
Volume 134, Issue 8, Pages -Publisher
COMPANY BIOLOGISTS LTD
DOI: 10.1242/jcs.254888
Keywords
Hippo pathway; PAR1; PAR2; Thrombin; S1P; LPA
Categories
Funding
- National Institutes of Health [R35 GM127121]
- Ben and Catherine Ivy Foundation
- Howard Hughes Medical Institute Gilliam Pre-doctoral Fellowship
- National Cancer Institute of the National Institutes of Health [T32CA080416]
Ask authors/readers for more resources
The study reveals the important role of ARRDC3 in regulating the GPCR and Hippo signaling pathways in TNBC, showing that ARRDC3 suppresses PAR1-induced Hippo signaling to inhibit migration and invasion of TNBC.
The alpha-arrestin domain containing protein 3 (ARRDC3) is a tumor suppressor in triple-negative breast carcinoma (TNBC), a highly metastatic subtype of breast cancer that lacks targeted therapies. Thus, understanding the mechanisms and targets of ARRDC3 in TNBC is important. ARRDC3 regulates trafficking of protease-activated receptor 1 (PAR1, also known as F2R), a G-protein-coupled receptor (GPCR) implicated in breast cancer metastasis. Loss of ARRDC3 causes overexpression of PAR1 and aberrant signaling. Moreover, dysregulation of GPCR-induced Hippo signaling is associated with breast cancer progression. However, the mechanisms responsible for Hippo dysregulation remain unknown. Here, we report that the Hippo pathway transcriptional co-activator TAZ (also known as WWTR1) is the major effector of GPCR signaling and is required for TNBC migration and invasion. Additionally, ARRDC3 suppresses PAR1-induced Hippo signaling via sequestration of TAZ, which occurs independently of ARRDC3-regulated PAR1 trafficking. The ARRDC3 C-terminal PPXY motifs and TAZ WW domain are crucial for this interaction and are required for suppression of TNBC migration and lung metastasis in vivo. These studies are the first to demonstrate a role for ARRDC3 in regulating GPCR-induced TAZ activity in TNBC and reveal multi-faceted tumor suppressor functions of ARRDC3. This article has an associated First Person interview with the first author of the paper.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available